PRELUDE THERAPEUTICS INC Revenue
PRELUDE THERAPEUTICS INC (PRLD) reported Revenue of $5.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $5.70M.
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $4.58M.
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $5.64M, a 41.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $6.50M, a 116.67% increase year-over-year.
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $12.14M, a 73.43% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.70M 10-Q · filed 2026-08-11 | $10.28M 10-Q · filed 2026-08-11 | $15.92M derived: sum of 3 quarters · filed 2026-08-11 | $22.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.58M 10-Q · filed 2026-05-12 | $10.22M derived: sum of 2 quarters · filed 2026-05-12 | $16.72M derived: sum of 3 quarters · filed 2026-05-12 | $16.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $12.14M derived: sum of 2 quarters · filed 2026-03-10 | $12.14M derived: sum of 3 quarters · filed 2026-08-11 | $12.14M 10-K · filed 2026-03-10 |
| 2025-09-30 | $6.50M 10-Q · filed 2025-11-12 | $6.50M derived: sum of 2 quarters · filed 2026-08-11 | $6.50M 10-Q · filed 2025-11-12 | $10.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $4.00M derived: sum of 3 quarters · filed 2026-08-11 | $7.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $4.00M derived: sum of 2 quarters · filed 2026-05-12 | $7.00M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.00M derived: sum of 2 quarters · filed 2026-03-10 | $7.00M 10-K · filed 2026-03-10 | |
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-12 | $3.00M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |